PG201 is a prescription drug for osteoarthritis and is the 7th botanical drug that has ever been approved by the MFDS (Ministry of Food and Drug Safety) in 2012. It is being sold under the brand name “LAYLA Tab” and has been generating a domestic annual revenue of 20 billion KRW since it has been licensed out to PMG Pharma.
PG201 showed significant improvement in various animal models of osteoarthritis and rheumatoid arthritis. In addition, it has been founded that it can prevent cartilage destruction by regulating the expression of cartilage degradation enzymes unlike conventional anti-inflammatory analgesic drugs such as NSAIDs. PG201 has proved its safety and efficacy on patients with osteoarthritis by conducting phase II and phase III clinical trials.